Houston MD Grounded by DEA Over Medicare Ban and Prescription Woes
Published Date: 9/23/2025
Notice
Summary
Dr. Rachel Kientcha-Tita from Houston lost her DEA registration because she’s barred from Medicare, Medicaid, and other federal health programs. The DEA officially revoked her license and denied her renewal after a thorough review and hearing. This means she can’t legally prescribe controlled substances through federal programs anymore, effective immediately.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked and Denied
DEA Certificate of Registration No. FK0843462 for Rachel Kientcha‑Tita, M.D., is revoked and any pending renewal or modification is denied. The Order also denies any other pending application by Dr. Kientcha‑Tita for registration in Texas. This Order is effective October 23, 2025.
Fifteen‑Year Federal Exclusion (Medicare/Medicaid)
The U.S. Department of Health and Human Services, Office of Inspector General excluded Rachel Kientcha‑Tita, M.D., from Medicare, Medicaid, and all federal health care programs effective August 20, 2017, for a period of fifteen years (through August 20, 2032). Because of that exclusion, DEA found she has been and remains excluded and revoked and denied her DEA registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-18361 — Immacula Michel, M.D.; Decision and Order
Dr. Immacula Michel from Florida tried to get a DEA registration but didn’t follow the rules by prescribing controlled drugs without proper registration. Because she didn’t respond or ask for a hearing in time, her application was denied. This means she can’t legally prescribe controlled substances, and the decision is final as of September 2025.
Next: 2025-18363 — Self-Regulatory Organizations; Fixed Income Clearing Corporation; Notice of Filing of Amendment No. 1, and Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change, as Modified by Amendment No. 1, To Modify the GSD Rulebook Relating to Default Management and Porting With Respect to Indirect Participant Activity
The Fixed Income Clearing Corporation (FICC) wants to update its rules to better handle what happens if a company using its services can’t pay up, especially for indirect participants who use middlemen. These changes aim to make it easier to move accounts between intermediaries and improve how defaults are managed. The SEC is reviewing these updates and asking for public feedback before deciding, with potential impacts on how money and risks are handled in the system.